Applying biopharma rigor to the vast
therapeutic potential of the endocannabinoid system
Modulating the endocannabinoid system is among the most promising fields in the pharmaceutical industry. At Artelo Biosciences®, we’re applying true biopharma discipline toward developing and commercializing a diverse portfolio of novel therapeutic candidates targeting the endocannabinoid system.
How we’re delivering on the promise of the endocannabinoid system (ECS)
Understanding the science
We believe a biopharma approach will lead to novel and high-impact therapeutics which harness the full potential of the ECS
A portfolio-based strategy
Our diverse set of programs are focused on a broad portfolio of assets with three distinct mechanisms to modulate the ECS
Our proven leadership team
We have decades of experience in biopharmaceutical development, commercialization, and ECS science